Implication of the New AJCC pT Classification of SCC of the Lip Comparing With Other Oral Subsites

Carregando...
Imagem de Miniatura
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Citação
LARYNGOSCOPE, v.131, n.11, p.E2770-E2776, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective To determine the implication of the new AJCC staging system for pT classification in a cohort of patients with SCC of the lip mucosa and compare it to other oral cavity sites. Methods Retrospective cohort of 744 patients treated between 2002 and 2017, by the Head and Neck Surgery Department of the University of Sao Paulo. Results Of 95 lip patients, 42 had pT upstage (58.1% of pT1 to pT2-3 and 50% of pT2 to pT3). Similar DFS/OS observed for those pT1 maintained or upstaged to pT2-3, pT2 patients upstaged to pT3 presented worse OS (49.4% versus 92.3%, P = .032). The comparison between lip and other mouth topographies, denoted better prognosis for pT1-2, but not for pT3-4a. Lip tumors had lower DOI, rates of perineural/angiolymphatic invasion, nodal metastasis, recurrence, and death. Conclusion The inclusion of DOI to the new pT classification better stratifies patients with SCC of the lip mucosa upstaged to pT3 by assessing inferior OS. Level of Evidence 3 Laryngoscope, 2021
Palavras-chave
Lip, oral cavity neoplasms, neoplasm staging, recurrence, survival
Referências
  1. Alkureishi LWT, 2008, LARYNGOSCOPE, V118, P629, DOI 10.1097/MLG.0b013e31815e8bf0
  2. Amin MB, 2017, AJCC CANC STAGING MA, V8th, DOI 10.1007/978-3-319-40618-3
  3. Bota JP, 2017, DERMATOL SURG, V43, P494, DOI 10.1097/DSS.0000000000001020
  4. Caldeira PC, 2020, ORAL DIS, V26, P1357, DOI 10.1111/odi.13194
  5. de Matos LL, 2014, OR SURG OR MED OR PA, V118, P209, DOI 10.1016/j.oooo.2014.03.023
  6. Dirven R, 2017, ORAL ONCOL, V74, P30, DOI 10.1016/j.oraloncology.2017.09.007
  7. Faisal M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202632
  8. Huang SH, 2009, CANCER-AM CANCER SOC, V115, P1489, DOI 10.1002/cncr.24161
  9. Kano S, 2018, INT J CLIN ONCOL, V23, P844, DOI 10.1007/s10147-018-1276-5
  10. Kavabata NK, 2019, EUR ARCH OTO-RHINO-L, V276, P2047, DOI 10.1007/s00405-019-05457-x
  11. Kozak MM, 2019, LARYNGOSCOPE, V129, P2082, DOI 10.1002/lary.27753
  12. Matos LL, 2017, ORAL ONCOL, V71, P47, DOI 10.1016/j.oraloncology.2017.05.020
  13. MOORE C, 1986, ARCH SURG-CHICAGO, V121, P1410
  14. Murthy S, 2019, J SURG ONCOL, V119, P449, DOI 10.1002/jso.25348
  15. Pentenero M, 2005, HEAD NECK-J SCI SPEC, V27, P1080, DOI 10.1002/hed.20275
  16. Rastogi S, 2019, CLIN ORAL INVEST, V23, P2071, DOI 10.1007/s00784-018-2589-5
  17. SHINGAKI S, 1988, ORAL SURG ORAL MED O, V66, P683, DOI 10.1016/0030-4220(88)90318-0
  18. SPIRO RH, 1986, AM J SURG, V152, P345, DOI 10.1016/0002-9610(86)90302-8
  19. Tam S, 2019, HEAD NECK-J SCI SPEC, V41, P177, DOI 10.1002/hed.25506